Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Puerto Rico has been witnessing a steady growth in recent years.
Customer preferences: Puerto Rican customers have been showing an increasing demand for Anti-Hypertensive Drugs due to the high prevalence of hypertension in the country. The aging population, unhealthy eating habits, and sedentary lifestyles have contributed significantly to the rise in hypertension cases.
Trends in the market: The market for Anti-Hypertensive Drugs in Puerto Rico has been growing steadily due to the increasing number of hypertension patients. The market has been witnessing a shift towards combination drugs, which offer better efficacy and convenience to patients. The use of fixed-dose combination drugs has been on the rise, as they offer a more convenient dosing regimen and better compliance. There has also been a trend towards the use of generic drugs, which are more affordable and accessible to a larger section of the population.
Local special circumstances: Puerto Rico has a unique healthcare system, which is a blend of public and private healthcare. The government provides healthcare services to a significant portion of the population through various programs such as Medicaid and Medicare. The private healthcare sector is also significant and provides healthcare services to a large section of the population. The availability of healthcare services, including Anti-Hypertensive Drugs, is relatively good in Puerto Rico.
Underlying macroeconomic factors: Puerto Rico is an unincorporated territory of the United States, and its economy is closely linked to that of the US. The island has been facing economic challenges in recent years, with a high debt burden and slow economic growth. The healthcare sector, however, has been growing steadily and has been a significant contributor to the economy. The availability of healthcare services, including Anti-Hypertensive Drugs, is relatively good in Puerto Rico due to the presence of a well-developed healthcare infrastructure.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
